Antifungal therapy in European hospitals: Data from the ESAC point-prevalence surveys 2008 and 2009

P. Zarb, B. Amadeo, A. Muller, N. Drapier, V. Vankerckhoven, P. Davey, H. Goossens, Sigrid Metz-Gercek, Hilde Jansens, Boyka Markova, Christiana Kontemeniotou, Arjana Andrasevic, Jiri Vlcek, Niels Frimodt-Møller, Piret Mitt, Outi Lyytikainen, Xavier Bertrand, Katja de With, Anastasia Antoniadou, G. TernákRobert Cunney, Raul Raz, Silvio Brusaferro, Elina Dimina, Vitalija Butkyte, Bruch Marcel, Jon Birger Haug, Janina Pawlowksa, Ines Teixeira, Svetlana Ratchina, Milan Cizman, Mercedes Sora, Gunilla Skoog, Giorgio Zanetti, Margreet Filius, Yesim Cetinkaya Sardan, Jonathan Cooke, Hugh Webb, Margaret Heginbothom

Research output: Article

19 Citations (Scopus)

Abstract

The study aimed to identify targets for quality improvement in antifungal use in European hospitals and determine the variability of such prescribing. Hospitals that participated in the European Surveillance of Antimicrobial Consumption Point Prevalence Surveys (ESAC-PPS) were included. The WHO Anatomical Therapeutic Chemical (ATC) classification for 'antimycotics for systemic use' (J02) 2009 version was used. Demographic data and information about indications and diagnoses were collected in 2008 and 2009. From 99053 patients, 29324 (29.6%) received antimicrobials. Antifungals represented 1529 of 40878 (3.7%) antimicrobials. Antifungals were mainly (54.2%) administered orally. Hospital-acquired infections represented 44.5% of indications for antifungals followed by medical prophylaxis at 31.2%. The site of infection was not defined in 36.0% of cases but the most commonly targeted sites were respiratory (19.2%) and gastrointestinal (18.8%). The most used antifungal was fluconazole (60.5%) followed by caspofungin (10.5%). Antifungal-antibacterial combinations were frequently used (77.5%). The predominance of fluconazole use in participating hospitals could result in an increase in prevalence of inherently resistant fungi, increasing the need for newer antifungals. Although acknowledging that antifungal prophylaxis in the immunocompromised host needs further exploration, repetitive surveys using ESAC-PPS methodology may help to monitor the effects of interventions set to regulate antifungal use.

Original languageEnglish
JournalClinical Microbiology and Infection
Volume18
Issue number10
DOIs
Publication statusPublished - okt. 2012

Fingerprint

Fluconazole
caspofungin
Immunocompromised Host
Cross Infection
Quality Improvement
Fungi
Therapeutics
Demography
Infection
Surveys and Questionnaires

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Antifungal therapy in European hospitals : Data from the ESAC point-prevalence surveys 2008 and 2009. / Zarb, P.; Amadeo, B.; Muller, A.; Drapier, N.; Vankerckhoven, V.; Davey, P.; Goossens, H.; Metz-Gercek, Sigrid; Jansens, Hilde; Markova, Boyka; Kontemeniotou, Christiana; Andrasevic, Arjana; Vlcek, Jiri; Frimodt-Møller, Niels; Mitt, Piret; Lyytikainen, Outi; Bertrand, Xavier; de With, Katja; Antoniadou, Anastasia; Ternák, G.; Cunney, Robert; Raz, Raul; Brusaferro, Silvio; Dimina, Elina; Butkyte, Vitalija; Marcel, Bruch; Haug, Jon Birger; Pawlowksa, Janina; Teixeira, Ines; Ratchina, Svetlana; Cizman, Milan; Sora, Mercedes; Skoog, Gunilla; Zanetti, Giorgio; Filius, Margreet; Sardan, Yesim Cetinkaya; Cooke, Jonathan; Webb, Hugh; Heginbothom, Margaret.

In: Clinical Microbiology and Infection, Vol. 18, No. 10, 10.2012.

Research output: Article

Zarb, P, Amadeo, B, Muller, A, Drapier, N, Vankerckhoven, V, Davey, P, Goossens, H, Metz-Gercek, S, Jansens, H, Markova, B, Kontemeniotou, C, Andrasevic, A, Vlcek, J, Frimodt-Møller, N, Mitt, P, Lyytikainen, O, Bertrand, X, de With, K, Antoniadou, A, Ternák, G, Cunney, R, Raz, R, Brusaferro, S, Dimina, E, Butkyte, V, Marcel, B, Haug, JB, Pawlowksa, J, Teixeira, I, Ratchina, S, Cizman, M, Sora, M, Skoog, G, Zanetti, G, Filius, M, Sardan, YC, Cooke, J, Webb, H & Heginbothom, M 2012, 'Antifungal therapy in European hospitals: Data from the ESAC point-prevalence surveys 2008 and 2009', Clinical Microbiology and Infection, vol. 18, no. 10. https://doi.org/10.1111/j.1469-0691.2012.03973.x
Zarb, P. ; Amadeo, B. ; Muller, A. ; Drapier, N. ; Vankerckhoven, V. ; Davey, P. ; Goossens, H. ; Metz-Gercek, Sigrid ; Jansens, Hilde ; Markova, Boyka ; Kontemeniotou, Christiana ; Andrasevic, Arjana ; Vlcek, Jiri ; Frimodt-Møller, Niels ; Mitt, Piret ; Lyytikainen, Outi ; Bertrand, Xavier ; de With, Katja ; Antoniadou, Anastasia ; Ternák, G. ; Cunney, Robert ; Raz, Raul ; Brusaferro, Silvio ; Dimina, Elina ; Butkyte, Vitalija ; Marcel, Bruch ; Haug, Jon Birger ; Pawlowksa, Janina ; Teixeira, Ines ; Ratchina, Svetlana ; Cizman, Milan ; Sora, Mercedes ; Skoog, Gunilla ; Zanetti, Giorgio ; Filius, Margreet ; Sardan, Yesim Cetinkaya ; Cooke, Jonathan ; Webb, Hugh ; Heginbothom, Margaret. / Antifungal therapy in European hospitals : Data from the ESAC point-prevalence surveys 2008 and 2009. In: Clinical Microbiology and Infection. 2012 ; Vol. 18, No. 10.
@article{6b71925ab1a944468e72fa606fd1267d,
title = "Antifungal therapy in European hospitals: Data from the ESAC point-prevalence surveys 2008 and 2009",
abstract = "The study aimed to identify targets for quality improvement in antifungal use in European hospitals and determine the variability of such prescribing. Hospitals that participated in the European Surveillance of Antimicrobial Consumption Point Prevalence Surveys (ESAC-PPS) were included. The WHO Anatomical Therapeutic Chemical (ATC) classification for 'antimycotics for systemic use' (J02) 2009 version was used. Demographic data and information about indications and diagnoses were collected in 2008 and 2009. From 99053 patients, 29324 (29.6{\%}) received antimicrobials. Antifungals represented 1529 of 40878 (3.7{\%}) antimicrobials. Antifungals were mainly (54.2{\%}) administered orally. Hospital-acquired infections represented 44.5{\%} of indications for antifungals followed by medical prophylaxis at 31.2{\%}. The site of infection was not defined in 36.0{\%} of cases but the most commonly targeted sites were respiratory (19.2{\%}) and gastrointestinal (18.8{\%}). The most used antifungal was fluconazole (60.5{\%}) followed by caspofungin (10.5{\%}). Antifungal-antibacterial combinations were frequently used (77.5{\%}). The predominance of fluconazole use in participating hospitals could result in an increase in prevalence of inherently resistant fungi, increasing the need for newer antifungals. Although acknowledging that antifungal prophylaxis in the immunocompromised host needs further exploration, repetitive surveys using ESAC-PPS methodology may help to monitor the effects of interventions set to regulate antifungal use.",
keywords = "Fluconazole, Hospital antifungal consumption, Hospital-acquired infections, Medical prophylaxis, Point-prevalence surveys",
author = "P. Zarb and B. Amadeo and A. Muller and N. Drapier and V. Vankerckhoven and P. Davey and H. Goossens and Sigrid Metz-Gercek and Hilde Jansens and Boyka Markova and Christiana Kontemeniotou and Arjana Andrasevic and Jiri Vlcek and Niels Frimodt-M{\o}ller and Piret Mitt and Outi Lyytikainen and Xavier Bertrand and {de With}, Katja and Anastasia Antoniadou and G. Tern{\'a}k and Robert Cunney and Raul Raz and Silvio Brusaferro and Elina Dimina and Vitalija Butkyte and Bruch Marcel and Haug, {Jon Birger} and Janina Pawlowksa and Ines Teixeira and Svetlana Ratchina and Milan Cizman and Mercedes Sora and Gunilla Skoog and Giorgio Zanetti and Margreet Filius and Sardan, {Yesim Cetinkaya} and Jonathan Cooke and Hugh Webb and Margaret Heginbothom",
year = "2012",
month = "10",
doi = "10.1111/j.1469-0691.2012.03973.x",
language = "English",
volume = "18",
journal = "Clinical Microbiology and Infection",
issn = "1198-743X",
publisher = "Elsevier Limited",
number = "10",

}

TY - JOUR

T1 - Antifungal therapy in European hospitals

T2 - Data from the ESAC point-prevalence surveys 2008 and 2009

AU - Zarb, P.

AU - Amadeo, B.

AU - Muller, A.

AU - Drapier, N.

AU - Vankerckhoven, V.

AU - Davey, P.

AU - Goossens, H.

AU - Metz-Gercek, Sigrid

AU - Jansens, Hilde

AU - Markova, Boyka

AU - Kontemeniotou, Christiana

AU - Andrasevic, Arjana

AU - Vlcek, Jiri

AU - Frimodt-Møller, Niels

AU - Mitt, Piret

AU - Lyytikainen, Outi

AU - Bertrand, Xavier

AU - de With, Katja

AU - Antoniadou, Anastasia

AU - Ternák, G.

AU - Cunney, Robert

AU - Raz, Raul

AU - Brusaferro, Silvio

AU - Dimina, Elina

AU - Butkyte, Vitalija

AU - Marcel, Bruch

AU - Haug, Jon Birger

AU - Pawlowksa, Janina

AU - Teixeira, Ines

AU - Ratchina, Svetlana

AU - Cizman, Milan

AU - Sora, Mercedes

AU - Skoog, Gunilla

AU - Zanetti, Giorgio

AU - Filius, Margreet

AU - Sardan, Yesim Cetinkaya

AU - Cooke, Jonathan

AU - Webb, Hugh

AU - Heginbothom, Margaret

PY - 2012/10

Y1 - 2012/10

N2 - The study aimed to identify targets for quality improvement in antifungal use in European hospitals and determine the variability of such prescribing. Hospitals that participated in the European Surveillance of Antimicrobial Consumption Point Prevalence Surveys (ESAC-PPS) were included. The WHO Anatomical Therapeutic Chemical (ATC) classification for 'antimycotics for systemic use' (J02) 2009 version was used. Demographic data and information about indications and diagnoses were collected in 2008 and 2009. From 99053 patients, 29324 (29.6%) received antimicrobials. Antifungals represented 1529 of 40878 (3.7%) antimicrobials. Antifungals were mainly (54.2%) administered orally. Hospital-acquired infections represented 44.5% of indications for antifungals followed by medical prophylaxis at 31.2%. The site of infection was not defined in 36.0% of cases but the most commonly targeted sites were respiratory (19.2%) and gastrointestinal (18.8%). The most used antifungal was fluconazole (60.5%) followed by caspofungin (10.5%). Antifungal-antibacterial combinations were frequently used (77.5%). The predominance of fluconazole use in participating hospitals could result in an increase in prevalence of inherently resistant fungi, increasing the need for newer antifungals. Although acknowledging that antifungal prophylaxis in the immunocompromised host needs further exploration, repetitive surveys using ESAC-PPS methodology may help to monitor the effects of interventions set to regulate antifungal use.

AB - The study aimed to identify targets for quality improvement in antifungal use in European hospitals and determine the variability of such prescribing. Hospitals that participated in the European Surveillance of Antimicrobial Consumption Point Prevalence Surveys (ESAC-PPS) were included. The WHO Anatomical Therapeutic Chemical (ATC) classification for 'antimycotics for systemic use' (J02) 2009 version was used. Demographic data and information about indications and diagnoses were collected in 2008 and 2009. From 99053 patients, 29324 (29.6%) received antimicrobials. Antifungals represented 1529 of 40878 (3.7%) antimicrobials. Antifungals were mainly (54.2%) administered orally. Hospital-acquired infections represented 44.5% of indications for antifungals followed by medical prophylaxis at 31.2%. The site of infection was not defined in 36.0% of cases but the most commonly targeted sites were respiratory (19.2%) and gastrointestinal (18.8%). The most used antifungal was fluconazole (60.5%) followed by caspofungin (10.5%). Antifungal-antibacterial combinations were frequently used (77.5%). The predominance of fluconazole use in participating hospitals could result in an increase in prevalence of inherently resistant fungi, increasing the need for newer antifungals. Although acknowledging that antifungal prophylaxis in the immunocompromised host needs further exploration, repetitive surveys using ESAC-PPS methodology may help to monitor the effects of interventions set to regulate antifungal use.

KW - Fluconazole

KW - Hospital antifungal consumption

KW - Hospital-acquired infections

KW - Medical prophylaxis

KW - Point-prevalence surveys

UR - http://www.scopus.com/inward/record.url?scp=84866165439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866165439&partnerID=8YFLogxK

U2 - 10.1111/j.1469-0691.2012.03973.x

DO - 10.1111/j.1469-0691.2012.03973.x

M3 - Article

C2 - 22827696

AN - SCOPUS:84866165439

VL - 18

JO - Clinical Microbiology and Infection

JF - Clinical Microbiology and Infection

SN - 1198-743X

IS - 10

ER -